Li Xiao

This inventor holds 25 USPTO granted patents and 4 published patent applications and 14 EPO patents, primarily in Drug Discovery. Top assignees: Merck Sharp + Dohme Corp., Schering Corporation, Merck Sharp & Dohme LLC. Active years: 2007-2026.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Li Xiao. Retrieved from https://idiyas.com/inventor/li-xiao-0rq9ka9z

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Calculating rank

USPTO Granted Patents = 25 (Patent Applications = 4)

% Patents Active = 64.0

EPO Patents = 14 (Patent Applications = 15)

Average Co-Inventor Count = 11.0

ph-index = 5

Forward Citations = 110(Granted Patents)

Location History:

Woodbridge, NJ (US) (2007 - 2008)
Cranbury, NJ (US) (2009 - 2024)

Company Filing History:

15 out of 2,405

Merck Sharp + Dohme Corp.

Merck Sharp & Dohme LLC

patents

Years Active: 2007-2026

Loading Chart...

Areas of Expertise:

Indoleamine Inhibitors

Metallo-Beta-Lactamase

Kinase Inhibitors

Pyrazole Compounds

Piperazine Amides

Bicyclo Compounds

Orexin Receptor Agonists

C.difficile Toxin

Polynucleotides

PDE4 Inhibitors

ADAM33

ERK Inhibitors

25 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12760005 - Bicycloheptane pyrrolidine orexin receptor agonists (2026-10-13),

2. 12576087 - Aryloxypiperidine pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors (2026-03-17),

3. 12264134 - Substituted piperazine amide compounds as indoleamine 2,3-dioxygenase (IDO) inhibitors (2025-04-01),

4. 12152019 - Arylalkyl pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors (2024-11-26),

5. 12091405 - Substituted pyrazole compounds as indoleamine 2,3-dioxygenase inhibitors (2024-09-17),

6. 11992489 - Substituted tetrahydroquinoline compounds as indoleamine 2,3-dioxygenase inhibitors (2024-05-28),

7. 11680060 - Bicycloheptane pyrrolidine orexin receptor agonists (2023-06-20),

8. 11478461 - [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors (2022-10-25),

9. 11352320 - Substituted [1.1.1] bicyclo compounds as indoleamine 2,3-dioxygenase inhibitors (2022-06-07),

10. 11207312 - Metallo-beta-lactamase inhibitors and methods of use thereof (2021-12-28),

11. 10544130 - Metallo-beta-lactamase inhibitors (2020-01-28),

12. 10227331 - Metallo-β-lactamase inhibitors (2019-03-12),

13. 10221163 - Metallo-beta-lactamase inhibitors (2019-03-05),

14. 9839642 - Beta-tetrazolyl-propionic acids as metallo-beta-lactamase inhibitors (2017-12-12),

15. 9708336 - Metallo-beta-lactamase inhibitors (2017-07-18),

Title: The Innovator Story of Li Xiao: Pioneering Inventions in Cranbury, NJ

Introduction:

In the realm of groundbreaking inventions and patents, Li Xiao stands out as a notable inventor based in Cranbury, New Jersey. With a remarkable portfolio comprising 19 patents, Li Xiao has made significant contributions to the fields of neuroscience and pharmaceuticals.

Latest Patents:

Li Xiao's recent patents are at the forefront of innovation in pharmaceuticals. One notable invention involves bicyclo[4.1.0]heptane pyrrolidine compounds that function as agonists of orexin receptors. These compounds hold promise for treating various neurological and psychiatric disorders. Another patent showcases compounds that act as inhibitors of an IDO enzyme, offering potential solutions for IDO-associated diseases.

Career Highlights:

Having worked at esteemed companies such as Merck Sharp & Dohme Corporation and Schering Corporation, Li Xiao has honed her skills and expertise in the pharmaceutical industry. Her innovative mindset and dedication to advancing healthcare have been evident throughout her career, leading to the creation of impactful patents.

Collaborations:

Throughout her professional journey, Li Xiao has collaborated with talented individuals in the field. Notable coworkers include Dexi Yang and Alexander Pasternak, who have contributed to the development and success of various projects alongside Li Xiao. These collaborations have fostered a culture of innovation and shared knowledge in the workplace.

Conclusion:

In conclusion, Li Xiao's inventive spirit and contributions to the pharmaceutical industry portray her as a visionary inventor. With a keen focus on developing solutions for complex diseases, Li Xiao's patents pave the way for future advancements in healthcare. Her collaborations and career highlights underscore her commitment to innovation, making her a prominent figure in the world of inventions and patents.

Profile summary based on public USPTO records.